The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia

BACKGROUND: A recent study demonstrating the use of Therapeutic Drug Monitoring (TDM) in patients with chronic myeloid leukemia (CML) resulted in a higher response rate with imatinib (IM) than demonstrated in second-generation tyrosine kinase inhibitor studies. The cost-effectiveness of TDM combined...

Descripción completa

Detalles Bibliográficos
Autores principales: Conti, Rena M, Padula, William V, Becker, Russell V, Salamone, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390998/
https://www.ncbi.nlm.nih.gov/pubmed/34337991
http://dx.doi.org/10.18553/jmcp.2021.27.8.1077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390998/
https://www.ncbi.nlm.nih.gov/pubmed/34337991
http://dx.doi.org/10.18553/jmcp.2021.27.8.1077

Ejemplares similares